Filing Details
- Accession Number:
- 0001209191-21-068262
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-07 10:42:20
- Reporting Period:
- 2021-12-06
- Accepted Time:
- 2021-12-07 10:42:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
885978 | U S Physical Therapy Inc | USPH | Services-Health Services (8000) | 760364866 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1519948 | D. Graham Reeve | 1300 W Sam Houston Pkwy S Suite 300 Houston TX 77042 | Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-12-06 | 1,000 | $94.19 | 7,845 | No | 4 | S | Indirect | Reeve trust |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | Reeve trust |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 12,217 | Direct |
Footnotes
- Includes 12,217 shares which restrictions lapse as to 1,912 shares on January 1, 2022; 1,433 on each of April 1, July 1 and October 1, 2022; 1,448 shares on January 1, 2023; 788 shares on each of April 1, July 1 and October 1, 2023; 794 shares on January 1, 2024; and 350 shares on each of April 1, July 1 and October 1, 2024 and January 1, 2025, if he is employed by the Company on those dates.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.00 to $94.42 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.